Soleno Therapeutics (SLNO) Short term Debt (2013 - 2014)
Soleno Therapeutics' (SLNO) quarterly Short term Debt came in at $101529.0 in Q4 2014, down 99.27% year-on-year from $14.0 million in Q4 2013, and down 99.27% on a QoQ basis from $14.0 million in Q4 2013.
Soleno Therapeutics (SLNO) Short term Debt (2013 - 2014) Analysis & Trends
Soleno Therapeutics (SLNO) has 2 years of Short term Debt data on file, last reported at $101529.0 in Q4 2014.
- On a quarterly basis, Short term Debt fell 99.27% year-over-year to $101529.0 in Q4 2014; TTM through Dec 2014 was $101529.0, a 99.27% decrease from a year earlier, with the FY2014 full-year figure at $101529.0, down 99.27% from the prior year.
- Short term Debt for Q4 2014 stood at $101529.0, down from $14.0 million in the prior quarter.
- Over the last five years, Short term Debt for SLNO reached as high as $14.0 million in Q4 2013 and fell as low as $101529.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Soleno Therapeutics | 874.25 Mn | 618.67 Mn | 93.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 101,529.00 |
| Dec 31, 2013 | 13.99 Mn |